2024-01-122024-01-122018-08-07Çağlar, İ. vd. (2018). ''Antifungal consumption, indications and selection of antifungal drugs in paediatric tertiary hospitals in Turkey: Results from the first national point prevalence survey''. Journal of Global Antimicrobial Resistance, 15, 232-238.2213-7165https://www.sciencedirect.com/science/article/pii/S2213716518301541https://hdl.handle.net/11452/38980Çalışmada 48 yazar bulunmaktadır. Bu yazarlardan sadece Bursa Uludağ Üniversitesi mensuplarının girişleri yapılmıştır.Objectives: The aim of this point prevalence survey was to evaluate the consumption, indications and strategies of antifungal therapy in the paediatric population in Turkey. Methods: A point prevalence study was performed at 25 hospitals. In addition to general data on paediatric units of the institutes, the generic name and indication of antifungal drugs, the presence of fungal isolation and susceptibility patterns, and the presence of galactomannan test and high-resolution computed tomography (HRCT) results were reviewed. Results: A total of 3338 hospitalised patients were evaluated. The number of antifungal drugs prescribed was 314 in 301 patients (9.0%). Antifungal drugs were mostly prescribed in paediatric haematology and oncology (PHO) units (35.2%), followed by neonatal ICUs (NICUs) (19.6%), paediatric services (18.3%), paediatric ICUs (PICUs) (14.6%) and haematopoietic stem cell transplantation (HSCT) units (7.3%). Antifungals were used for prophylaxis in 147 patients (48.8%) and for treatment in 154 patients (50.0%). The antifungal treatment strategy in 154 patients was empirical in 77 (50.0%), diagnostic-driven in 29 (18.8%) and targeted in 48 (31.2%). At the point of decision-making for diagnostic-driven antifungal therapy in 29 patients, HRCT had not been performed in 1 patient (3.4%) and galactomannan test results were not available in 12 patients (41.4%). Thirteen patients (8.4%) were receiving eight different antifungal combination therapies. Conclusion: The majority of antifungal drugs for treatment and prophylaxis were prescribed in PHO and HSCT units (42.5%), followed by ICUs. Thus, antifungal stewardship programmes should mainly focus on these patients within the availability of diagnostic tests of each hospitaleninfo:eu-repo/semantics/closedAccessInfectious diseasesPharmacology & pharmacyAntifungalsPaediatric tertiary hospitalPoint prevalence surveyIndicationsInfectious-diseases societyInvasive fungal-infectionsNeutropenic patientsLeukemia patients2016 updateHigh-riskGuidelinesChemotherapyCancerAspergillosisAntifungal agentsDrug prescriptionsHospitals, pediatricHumansPrevalenceSurveys and questionnairesTertiary care centersTurkeyArticle0004525550000482-s2.0-850563090582322381530121343https://doi.org/10.1016/j.jgar.2018.08.007Infectious diseasesPharmacology & pharmacyInvasive Aspergillosis; Mycoses; Systemic MycosisAmphotericin B deoxycholateAmphotericin B lipid complexAntifungal agentCaspofunginFluconazoleGalactomannanMicafunginPosaconazoleVoriconazoleAntifungal agenAcute lymphoblastic leukemiaAcute myeloid leukemiaAntifungal susceptibilityAntifungal therapyArticleCardiovascular diseaseCerebral palsyChronic respiratory tract diseaseComputer assisted tomographyDrug indicationDrug useFungus isolationHematopoietic stem cell transplantationHospital patientHumanImmune deficiencyInvasive aspergillosisKidney diseaseKidney transplantationLiver transplantationMajor clinical studyMetabolic disorderMycosisNeurologic diseasePrematurityPrescriptionPriority journalTurkey (republic)HospitalPrevalenceQuestionnaireTertiary care centerTurkey (bird)2213-7173